Drug Enforcement Administration
Audit of the Drug Enforcement Administration's Community-Based Efforts to Combat the Opioid Crisis
The OIG is conducting an audit of the DEA's community-based efforts to combat the opioid crisis. The preliminary objectives are to: (1) examine the DEA’s pilot city-selection methodology, (2) assess the DEA’s integration of a performance measurement strategy to enhance its community-based efforts, (3) evaluate the DEA’s collaboration with other agencies in combatting the opioid crisis, and (4) assess the DEA’s efforts to sustain progress in the communities it assists.
Audit of the Drug Enforcement Administration's Establishment and Oversight of DEA-Supported Foreign Law Enforcement Units
The OIG is conducting an audit of the Drug Enforcement Administration’s (DEA) establishment and oversight of DEA-supported foreign law enforcement units. The preliminary objectives are to: (1) evaluate the DEA’s process for establishing supported law enforcement units abroad, such as Sensitive Investigative Units, Vetted Units, and Protected Police Units; (2) determine if the DEA is effectively overseeing these units and safeguarding funds used to sustain these formal relationships; and (3) assess the DEA’s process for addressing allegations and specific instances of mismanagement, malfeasance, and waste associated with these units.
Audit of the Drug Enforcement Administration's Support Contracts for its Laboratory Information Management System
The OIG is auditing the Drug Enforcement Administration’s (DEA) support contracts for its Laboratory Information Management System (LIMS). The preliminary audit objective is to assess DEA’s administration of a bridge contract awarded to Abbott Informatics Corporation (Abbott) in March 2019, and relevant acquisition planning activities associated with a solicitation issued in November 2019. To accomplish this objective, we anticipate reviewing DEA’s plans for and oversight of LIMS support contracts, Abbott’s performance on the bridge contract, and pertinent performance and financial reporting requirements.
DEA's Income-Generating Undercover Operations
The OIG is conducting an audit of the DEA's income-generating undercover operations. The preliminary objectives are to evaluate the management and oversight of DEA’s income-generating operations with respect to: (1) the initiation and classification of these operations, (2) the controls over and use of funds during operations, and (3) the disposal of proceeds at the conclusion of these operations.
DEA's Prescription Drug Take Back Activities
The OIG is auditing DEA’s prescription drug take back activities. The preliminary objective is to evaluate the DEA’s policies, procedures, and practices for the collection, custody, and disposal of prescription drugs.
DOJ's Compliance with the Federal Funding Accountability and Transparency Act of 2006, as amended by the DATA Act of 2014
The OIG is examining DOJ's compliance with reporting requirements under the Federal Funding Accountability and Transparency Act, as amended by the DATA Act. Through memorandum M-15-12, Increasing Transparency of Federal Spending by Making Federal Spending Data Accessible, Searchable, and Reliable, the Office of Management and Budget provided guidance to federal agencies on the requirements that agencies must employ pursuant to the DATA Act. The OIG will review a statistically valid sampling of the fiscal year 2019 spending data submitted, and submit to Congress and make publicly available a report assessing the completeness, timeliness, quality, and accuracy of the data sampled.
To detect and deter waste, fraud, abuse, and misconduct in DOJ programs and personnel, and to promote economy and efficiency in those programs.